JP5576370B2 - Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 - Google Patents

Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 Download PDF

Info

Publication number
JP5576370B2
JP5576370B2 JP2011521675A JP2011521675A JP5576370B2 JP 5576370 B2 JP5576370 B2 JP 5576370B2 JP 2011521675 A JP2011521675 A JP 2011521675A JP 2011521675 A JP2011521675 A JP 2011521675A JP 5576370 B2 JP5576370 B2 JP 5576370B2
Authority
JP
Japan
Prior art keywords
chlorine
fluorine
alkyl
group
further substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011521675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530500A (ja
JP2011530500A5 (enExample
Inventor
ニンコヴィック サッシャ
フレデリック ブランガンザ ジョン
レイモンド コリンズ マイケル
チャールズ キャス ジョン
リ ホイ
タイラー リクター ダニエル
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2011530500A publication Critical patent/JP2011530500A/ja
Publication of JP2011530500A5 publication Critical patent/JP2011530500A5/ja
Application granted granted Critical
Publication of JP5576370B2 publication Critical patent/JP5576370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2011521675A 2008-08-06 2009-08-04 Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 Expired - Fee Related JP5576370B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8673208P 2008-08-06 2008-08-06
US61/086,732 2008-08-06
US22942809P 2009-07-29 2009-07-29
US61/229,428 2009-07-29
PCT/IB2009/053389 WO2010016005A1 (en) 2008-08-06 2009-08-04 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2011530500A JP2011530500A (ja) 2011-12-22
JP2011530500A5 JP2011530500A5 (enExample) 2012-09-13
JP5576370B2 true JP5576370B2 (ja) 2014-08-20

Family

ID=41171261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521675A Expired - Fee Related JP5576370B2 (ja) 2008-08-06 2009-08-04 Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物

Country Status (7)

Country Link
US (1) US8518952B2 (enExample)
EP (1) EP2328890B1 (enExample)
JP (1) JP5576370B2 (enExample)
AT (1) ATE542813T1 (enExample)
CA (1) CA2731368C (enExample)
ES (1) ES2378513T3 (enExample)
WO (1) WO2010016005A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2376485T3 (pl) 2008-12-19 2018-05-30 Vertex Pharmaceuticals Incorporated Pochodne pirazyny użyteczne jako inhibitory kinazy ATR
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2569287B1 (en) * 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
ES2575092T3 (es) 2011-06-27 2016-06-24 Janssen Pharmaceutica, N.V. Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
MX392542B (es) 2011-09-30 2025-03-24 Vertex Pharma Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr.
HUE046429T2 (hu) 2011-09-30 2020-03-30 Vertex Pharma ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
KR102171706B1 (ko) 2012-07-09 2020-10-30 얀센 파마슈티카 엔.브이. 포스포디에스테라아제 10 효소의 억제제
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
TWI623531B (zh) 2012-11-21 2018-05-11 Ｐｔｃ治療公司 經取代反向嘧啶ｂｍｉ－１抑制劑
CN103254121B (zh) * 2013-04-08 2015-08-26 洛阳师范学院 一种合成(3r,4r)-n-pg-4-甲基-3-甲胺基哌啶的方法
US10584115B2 (en) * 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
NZ720092A (en) 2013-12-05 2019-05-31 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
US9145393B2 (en) * 2014-01-24 2015-09-29 Confluence Life Sciences, Inc. Arylpyridinone ITK inhibitors for treating inflammation and cancer
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
BR112016026150B1 (pt) 2014-05-09 2019-11-05 Pimera Inc compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CA2984183C (en) 2015-05-01 2021-11-09 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
CN105130991B (zh) * 2015-07-10 2017-09-19 成都知普莱生物医药科技有限公司 一种合成骨形态发生蛋白受体抑制剂的方法
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
AU2017222417B2 (en) 2016-02-24 2020-07-09 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
WO2018140648A1 (en) 2017-01-25 2018-08-02 Eric Jon Jacobsen Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
CN107056681B (zh) * 2017-03-30 2019-10-01 广州白云山光华制药股份有限公司 一种托法替布中间体的制备方法
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
CN107474047B (zh) * 2017-08-29 2019-10-29 浙江工业大学 1,2,4-三唑并杂环类化合物的合成方法
CN107827811B (zh) * 2017-11-15 2021-01-29 上海皓伯化工科技有限公司 一种制备n-取代-1,2,3,6-四氢吡啶的方法
JP2021151955A (ja) * 2018-05-22 2021-09-30 株式会社カネカ 光学活性−ｃｉｓ−アミノピペリジンの製造方法
JP7478142B2 (ja) * 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
EP3608326A1 (en) 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
UY38705A (es) 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
EP3741762A1 (en) 2019-05-23 2020-11-25 Irbm S.P.A. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
EP3825318A1 (en) 2019-11-25 2021-05-26 Promidis S.r.l. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
MX2022015829A (es) * 2020-06-11 2023-04-05 Chdi Foundation Inc Compuestos heterocíclicos y agentes formadores de imágenes para formar la imagen de la proteína huntingtina.
WO2022026935A1 (en) * 2020-07-31 2022-02-03 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
KR102473645B1 (ko) * 2020-08-28 2022-12-05 (주)부흥산업사 (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
MX2024001193A (es) * 2021-07-30 2024-05-15 Childrens Hospital Med Ct Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a sarcoma felino de mcdonough (flt3) y usos de estos.
US20250346593A1 (en) * 2022-06-10 2025-11-13 Interline Therapeutics, Inc. Imidazo(1,2-1)pyridine derivatives as ripk2 inhibitors
AR129535A1 (es) 2022-06-21 2024-09-04 Syngenta Crop Protection Ag Derivados de carboxamida heterocíclicos bicíclicos microbiocidas
WO2024089191A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Microbiocidal heterobicyclic dihydrooxadiazine derivatives
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) * 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
PT1144609E (pt) 1999-08-27 2008-05-28 Novartis Vaccines & Diagnostic Oligonucleótidos anti-sentido quiméricos e suas formulações para transfecção de células
CA2385257A1 (en) 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
US6211164B1 (en) * 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
MX337162B (es) 2001-01-05 2016-02-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
EP1947102A1 (en) * 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
SG161745A1 (en) 2003-06-24 2010-06-29 Pfizer Prod Inc Processes for the preparation of 1-[(benzoimidazole-1 yl) quinolin-8-yl] piperidin-4-ylamine derivatives
US20080070930A1 (en) * 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
AU2008317406B2 (en) * 2007-10-25 2013-07-18 Merck Sharp & Dohme Corp. Therapeutic compounds

Also Published As

Publication number Publication date
ES2378513T3 (es) 2012-04-13
CA2731368C (en) 2013-05-14
US8518952B2 (en) 2013-08-27
ATE542813T1 (de) 2012-02-15
EP2328890B1 (en) 2012-01-25
EP2328890A1 (en) 2011-06-08
WO2010016005A1 (en) 2010-02-11
US20110144084A1 (en) 2011-06-16
JP2011530500A (ja) 2011-12-22
CA2731368A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
JP5576370B2 (ja) Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
CN115873020B (zh) Ras抑制剂
AU2019401466B2 (en) Compounds that participate in cooperative binding and uses thereof
CN101573358B (zh) 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
JP4792126B2 (ja) ピラゾール化合物およびＲａｆ阻害剤としてのその使用
CN102985417B (zh) 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
JP2024517847A (ja) Ｒａｓ阻害剤
US9018214B2 (en) Bicyclic heterocycle compounds and their uses in therapy
JP4523073B2 (ja) 癌を治療するためのＨＳＰ−９０阻害剤としての２−アミノ−５，７−ジヒドロ−６Ｈ−ピロロ［３，４−ｄ］ピリミジン誘導体
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
WO2007023382A2 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
AU2014244183A1 (en) Pyridine CDK9 kinase inhibitors
JP2020527174A (ja) Ａｔｒキナーゼの複素環式阻害剤
CA2887912A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2014013734A (es) Inhibidores de nampt.
TW202329937A (zh) 雙環胺ｃｋ１２抑制劑
WO2023233033A1 (en) Novel par-2 inhibitors
JP2011530580A (ja) 強力なｈｓｐ−９０阻害剤としての２−アミノピリミジン化合物
AU2017324281A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
KR20210100612A (ko) 시클로알칸-1,3-디아민 유도체
CA2824873A1 (en) Bicyclic carboxamide inhibitors of kinases
CN101663305A (zh) 作为hsp-90抑制剂用于治疗癌症的2-氨基-5,7-二氢-6h-吡咯并[3,4-d]嘧啶衍生物
US20250129100A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2024153077A1 (zh) Hpk1抑制剂及其制法和用途
CA3246917A1 (en) C-MYC MESSENGER RIBONUCLE ACID (MRNA) TRANSLATION MODULATORS AND THEIR USES IN CANCER TREATMENT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120730

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140703

R150 Certificate of patent or registration of utility model

Ref document number: 5576370

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees